8 appointments at our Malvern clinic over 14 weeks. The length of the appointments will vary from 30 min to 3 hours.
State of study
MK-1942 is a molecule that promotes the release of a chemical in the brain called glutamate. Glutamate release in the brain has been linked to improved cognition. This trial will investigate whether MK-1942 can improve cognitive when compared to placebo in people with mild to moderate Alzheimer's disease.
This study has been approved by the Bellberry Human Research Ethics Committee (2022-07-763)
We are seeking participants who meet the following criteria:
- have early Alzheimer’s disease
- be between 55 and 80 years old (inclusive).
- have a study partner (a next of kin or someone you have a close relationship to), who is willing to take part in the study and share information about you
- must be taking an approved Alzheimer's disease treatment (such as Aricept, Reminyl, Exelon, etc) and must be on a stable dose of that medication for at least 3 months.
- live in Victoria and can attend a clinic in Malvern
If you are interested in participating or would like more information please contact A/Prof Stephen Macfarlane (details below)
Level 1, 322 Glenferrie Road, Malvern VIC 3144
A/Prof Stephen Macfarlane
HammondCare Aged Psychiatry Clinical Trials (Malvern)
09 9597 6518